RT Journal Article SR Electronic T1 Multilevel Integrated Model with a Novel Systems Approach (MIMANSA) for Simulating the Spread of COVID-19 JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.05.12.20099291 DO 10.1101/2020.05.12.20099291 A1 Arpita Welling A1 Abhilasha Patel A1 Padmaj Kulkarni A1 Vinay G. Vaidya YR 2020 UL http://medrxiv.org/content/early/2020/06/18/2020.05.12.20099291.abstract AB Due to the spread of the coronavirus, public health officials grapple with multiple issues such as recommending a lockdown, contact tracing, promoting the use of masks, social distancing, frequent handwashing, as well as quarantining. It is even more challenging to find the optimal combination of these factors without the use of a suitable mathematical model.In this paper, we discuss a novel systems approach to building a model for simulating the spread of COVID-19. The model, MIMANSA, divides an individual’s in-person social interactions into three areas, namely home, workplace, and public places. The model tracks the in-person interactions and follows the virus spread. When a new silent carrier is created, the model automatically expands and builds a new layer in the network.MIMANSA has four control mechanisms, namely the exposure, infection rate, lockdown, and quarantining. MIMANSA differentiates between virus-infected patients, silent carriers, and healthy carriers. It can consider variations in virus activity levels of asymptomatic patients, varying the exposure to the virus, and varying the infection rate depending on the person’s immunity. MIMANSA can simulate scenarios to study the impact of many different conditions simultaneously. It could assist public health officials in complex decision making, enable scientists in projecting the SARS-CoV-2 virus spread and aid hospital administrators in the management of beds and equipment.MIMANSA is trained and validated using the data from the USA and India. Our results show that MIMANSA forecasts the number of COVID-19 cases in the USA, and India within a 3% margin of error.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not requiredAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data was obtained from the link given below. covid19india.org kaggle.com https:www.covid19India.org https://www.kaggle.com/imdevskp/corona-virus-report